“This move in Alnylam is crazy. I cannot believe what I’m seeing on my screen.”

That’s the text I received from a health care investor, who is long on Alnylam Pharmaceuticals (ALNY), when I asked him late Wednesday to explain the stock’s incredible 52 percent jump on the positive patisiran APOLLO study results announced hours earlier.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.